PietraGG. Histopathology of primary pulmonary hypertension. Chest1994;105(2, Suppl):2S–6S.
2.
DantzkerDR. Primary pulmonary hypertension: the American experience. Chest1994;105(2, Suppl):26S–28S.
3.
KinsellaJP, NeishSR, ShafferE, AbmanSH. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet1992;340(8823):819–820.
4.
RobertsJDJr, PolanerDM, LangP, ZapolWM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet1992;340(8823):818–819.
5.
SibbaldWJ, DriedgerAA, MyersML, ShortAI, WellsGA. Biventricular function in the adult respiratory distress syndrome. Chest1983;84(2):126–134.
6.
MelotC, LejeuneP, LeemanM, MoraineJJ, NacijeR.Prostaglandin E1 in the adult respiratory distress syndrome: benefit for pulmonary hypertension and cost for pulmonary gas exchange. Am Rev Respir Dis1989;139(1):106–110.
7.
RadermacherP, SantakB, WustHJ, TarnowJ, FalkeKJ. Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: effects on pulmonary capillary pressure and ventilation-perfusion distributions. Anesthesiology1990;72(2):238–244.
8.
MorleyD, MaragosCM, ZhangXY, BoignonM, WinkDA, KeeferLK. Mechanism of vascular relaxation induced by the nitric oxide (NO) nucleophile complexes, a new class of NO-based vasodilators. J Cardiovasc Pharmacol1993;21(4):670–676.
9.
IgnarroLJ, BugaGM, WoodKS, ByrnsRE, ChaudhuriG.Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA1987;84(24):9265–9269.
Pepke-ZabaJ, HigenbottamTW, Dinh-XuanAT, StoneD, WallworkJ.Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet1991;338(8776):1173–1174.
17.
GirardC, LehotJJ, PannetierJC, FilleyS, FrenchP, EstanoveS.Inhaled nitric oxide after mitral valve replacement in patients with chronic pulmonary artery hypertension. Anesthesiology1992;77(5):880–883.
18.
RossaintR, FalkeKJ, LopezF, SlamaK, PisonU, ZapolWM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med1993;328(6):399–405.
19.
BigatelloLM, HurfordWE, KacmarekRM, RobertsJDJr, ZapolWM. Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome: effects on pulmonary hemodynamics and oxygenation. Anesthesiology1994;80(4):761–770.
20.
ZapolWM, RimarS, GillisN, MarletteM, BoskenCH. Nitric oxide and the lung. Am J Respir Crit Care Med1994;149(5):1375–1380.
21.
GerlachH, PappertD, LewandoskiK, RossaintR, FalkeKJ. Long-term inhalation with evaluated low doses of nitric oxide for selective improvement of oxygenation in patients with adult respiratory distress syndrome. Intensive Care Med1993;19(8):443–449.
22.
PuybassetL, StewartT, RoubyJ-J, CluzelP, MourgeonE, BelinM-F, . Inhaled nitric oxide reverses the increase in pulmonary vascular resistance induced by permissive hypercapnia in patients with acute respiratory distress syndrome. Anesthesiology1994;80(6):1254–1267.
23.
BarnesPJ. Nitric oxide and airways. Eur Respir J1993;6(2):163–165.
24.
DavidsonD.NO bandwagon, yet. Inhaled nitric oxide (NO) for neonatal pulmonary hypertension (editorial). Am Rev Respir Dis1993;147(5):1078–1079.
25.
StamlerJS, SingelDJ, LoscalzoJ.Biochemistry of nitric oxide and its redox-activated forms. Science1992;258(5090):1898–1902.
FoubertL, FlemingB, LatimerR, JonasM, OduroA, BorlandC, HigenbottamT.Safety guidelines for use of nitric oxide (letter). Lancet1992;339(8809):1615–1616.
28.
MillerCC, MillerJWR. Pulmonary vascular smooth-muscle regulation: the role of inhaled nitric oxide gas. Respir Care1992;37(10):1175–1185.
RichS.The medical treatment of primary pulmonary hypertension: proven and promising strategies. Chest1994;105(2, Suppl):17S–20S.
33.
ButtAY, HigenbottamT.New therapies for primary pulmonary hypertension. Chest1994;105(2, Suppl):21S–25S.
34.
BrenotF.Primary pulmonary hypertension: case series from France. Chest1994;105(2, Suppl):33S–36S.
35.
OakleyCW. Primary pulmonary hypertension: case series from the United Kingdom. Chest1994;105(2, Suppl):29S–32S.
36.
RichS, KaufmannE, LevyPS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med1992;327(2):76–81.
37.
The International Primary Pulmonary Hypertension Study Group. The international primary pulmonary hypertension study (IPPHS). Chest1994;105(2, Suppl):37S–41S.
38.
RozkovecA, StadlingJR, ShepherdG, MacDermotJ, OakleyCM, DolleryCT. Prediction of favorable response to long-term vasodilation of pulmonary hypertension by short-term administration of epoprostenol (prostacyclin) or nifedipine. Br Heart J1988;59(6):696–705.
39.
SchranzD, ZeppF, IversenS, WippermanC, HuthR, ZimmerB, . Effects of tolazoline and prostacyclin on pulmonary hypertension in infants after cardiac surgery. Crit Care Med1992;20(9):1243–1249.
40.
BushA, BusstC, KnightWB, ShinebourneEA. Modification of pulmonary hypertension secondary to congenital heart disease by prostacyclin therapy. Am Rev Respir Dis1987;136:767–769.
41.
JonesDK, HigenbottamTW, WallworkJ.Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin). Br Heart J1987;57(3):270–278.
42.
RubinLJ, MendozaJ, HoodM, McGoonM, BarstR, WilliamsWB, . Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Ann Intern Med1990;112(2):485–491.
43.
KaukinenS, YlitaloP, PessiT, VapaatoloH.Hemodynamic effects of iloprost, a prostacyclin analogue. Clin Pharmacol Ther1984;36(4):464–469.
44.
ScottJP, HigenbottamTW, WallworkJ.The acute effect of the synthetic prostacyclin analogue iloprost in primary pulmonary hypertension. Br J Clin Pharmacol1990;44(6):231–234.
45.
MorganJM, McCormackDG, GriffithsMJ, MorganCJ, BarnesPJ, EvansTW. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation1991;84(3):1145–1149.
46.
InbarS, SchraderBJ, KaufmannE, VestalRE, RichS.Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension. J Am Coll Cardiol1993;21(2):413–418.
47.
SchraderBJ, InbarS, KaufmannL, VestalRE, RichS.Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol1992;19(5):1060–1064.
48.
OgilbyJD, IskandrianAS, UnterekerWJ, HeoJ, NguyenTN, MercuroJ.Effect of intravenous adenosine infusion on myocardial perfusion and function. Hemodynamic/angiographic and scintigraphic study. Circulation1992;86(3):887–895.
TanakaH, TajimiK, MoritsuneO, KobayashiK, OkadaK.Effects of milrinone on pulmonary vasculature in normal dogs and in dogs with pulmonary hypertension. Crit Care Med1991;19(1):68–74.
51.
MonradES, BaimDS, SmithHS, LanoueA, BraunwaldE, GrossmanW.Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. Circulation1985;71(5):972–979.
52.
BenottiJR, LeskoLJ, McCueJE, AlpertJS. Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. Am J Cardiol1985;56(10):685–689.
53.
EichhornEJ, KonstamMA, WeilandDS, RobertsDJ, MartinTT, StranskyNB, SalemDN. Differential effects of milrinone and dobutamine on right ventricular preload, afterload, and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol1987;60(16):1329–1333.
54.
FeneckRO and the European Milrinone Multicentre Trial Group. Intravenous milrinone following cardiac surgery: I. effects of bolus infusion followed by variable dose maintenance infusion. J Cardiothorac Vasc Anesth1992;6(5):554–562.
55.
FeneckRO and the European Milrinone Multicentre Trial Group. Intravenous milrinone following cardiac surgery: II. influence of patient factors and baseline haemodynamics on therapeutic response. J Cardiothorac Vasc Anesth1992;6(5):563–567.
56.
InoueA, YanagisawaM, KimuraS, KasuyaY, MiyauchiT, GotoK, MasakiT.The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by the separate genes. Proc Natl Acad Sci USA1989;86(8):2863–2867.
57.
StewartDJ, LevyRD, CernacekP, LanglebenD.Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?Ann Intern Med1991;114(6):464–469.
58.
IharaM, FukurodaT, SaekiT, NishikibeM, KojiriK, SudaH, YanoM.An endothelin receptor antagonist (ETA) isolated from Streptomyces misakiensis. Biochem Biophys Res Commun1991;178(1):132–137.
